ArticleThe Journal of investigative dermatology2015
Malignancies in pemphigus and pemphigoid diseases.
Article in The Journal of investigative dermatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Epidemiology of malignant tumors in patients with pemphigus: an analysis of trends from 1955 to 2021.Clinical and experimental medicine · 2024Pooled it
- Interventions for bullous pemphigoid.The Cochrane database of systematic reviews · 2023Pooled it
- Comorbidity in bullous pemphigoid: up-date and clinical implications.Frontiers in immunology · 2023Pooled it
- European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology - Part I.Journal of the European Academy of Dermatology and Venereology : JEADV · 2021Guideline
- Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial.Lancet (London, England) · 2017Trial
- Dipeptidyl Peptidase-4 Inhibitor Use and Risk of Pemphigus Vulgaris and Foliaceus: A Retrospective Cohort Study Using Databases of the Korea National Health Insurance Claims and the National Health Screening Examination.The Journal of dermatology · 2026Article
- Bullous pemphigoid.Nature reviews. Disease primers · 2025Review
- Bullous pemphigoid burden of disease, management and unmet therapeutic needs.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Review
- Concurrent presentation of acute lymphoblastic leukemia and bullous pemphigoid: a rare case report.Oxford medical case reports · 2025Article
- JAK-STAT pathway, type I/II cytokines, and new potential therapeutic strategy for autoimmune bullous diseases: update on pemphigus vulgaris and bullous pemphigoid.Frontiers in immunology · 2025Review
- Clinical Characteristics, Comorbidities, and Treatment in Patients with Pemphigus-A Single-Center Retrospective Study.Antibodies (Basel, Switzerland) · 2024Article
- Epidemiological Insights into Autoimmune Bullous Diseases in China: A Comprehensive Analysis.Journal of epidemiology and global health · 2024Article
- Acute myeloid leukemia with paraneoplastic pemphigus successfully treated with a personalized antileukemic and immunosuppressive strategy.Annals of hematology · 2024Article
- Relationship between bullous pemphigoid and malignancy: A Mendelian randomization study.The Journal of dermatology · 2024Article
- Coexistence of malignancies in pemphigus vulgaris.Immunologic research · 2023Article
- Prevalence, Spectrum and Clinical Implications of Malignancies in Patients with Bullous Pemphigoid.Acta dermato-venereologica · 2023Article
- Epidermolysis Bullosa Acquisita-Current and Emerging Treatments.Journal of clinical medicine · 2023Review
- What's new in the pathogeneses and triggering factors of bullous pemphigoid.The Journal of dermatology · 2023Review
- Pemphigus: trigger and predisposing factors.Frontiers in medicine · 2023Review
- Associations between bullous pemphigoid and hematological diseases: Literature review on mechanistic connections and possible treatments.Frontiers in immunology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
25560279What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.